Muhammad Tayyab Azam

Muhammad Tayyab Azam

Auto-generated profile, based on publicly available information

Muhammad Tayyab Azam

Dow university of health and sciences

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2026 in Journal of Pain & Palliative Care Pharmacotherapy
Verified
Journal Article
Closed access
MAMuhammad Tayyab Azam
Muhammad Tayyab Azam
ZSZain Ul Abideen Shahid
Zain Ul Abideen Shahid
MKMuhammad Arif Khan
Muhammad Arif Khan
SAShahzad Ashraf
Shahzad Ashraf
TATalha Aamir
Talha Aamir
SASaad Ashraf
Saad Ashraf
Postoperative pain remains a nearly universal experience, affecting up to 80% of surgical patients globally (1). Poorly controlled acute pain can delay recovery and also contributes to persistent p...

2 September 2026 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
MAMuhammad Tayyab Azam
Muhammad Tayyab Azam
MAMuhammad Hussain Azam
Muhammad Hussain Azam
MKMuhammad Arif Khan
Muhammad Arif Khan
MAMuhammad Hassan Azam
Muhammad Hassan Azam
ZSZain Ul Abideen Shahid
Zain Ul Abideen Shahid
HJHammad Javaid
Hammad Javaid
Background: Two-drug antiretroviral regimens are increasingly explored to simplify HIV-1 treatment while maintaining durable viral suppression. Doravirine combined with Islatravir (DOR/ISL) represents a novel non-integrase strand transfer inhibitor (non-INSTI) regimen. However, comprehensive synthesized evidence remains limited. Objectives: To systematically evaluate the efficacy and safety of fixed-dose Doravirine (100 mg) plus Islatravir (0.25 or 0.75 mg) for HIV-1 treatment in adults. Design: Systematic Review and Meta-Analysis. Data Sources and Methods: Comprehensive searches of PubMed, Embase, Scopus, Cochrane CENTRAL, ICTRP, and ClinicalTrials.gov were performed to identify RCTs evaluating Doravirine/Islatravir for HIV-1 treatment. The primary outcome was viral suppression (HIV-1 RNA <50 copies/mL) at 48 weeks. Secondary outcomes included immunological and safety endpoints. Results: Seven RCTs (N = 3,589) were included. In primary analyses restricted to the approved 0.25 mg dose (four RCTs, N = 1,639), DOR/0.25 mg ISL achieved non-inferior viral suppression compared to standard ART at 48 weeks (RR = 1.01, 95% CI: 0.97-1.04, p = 0.63), with consistent efficacy across virologically suppressed and treatment-naïve cohorts. DOR/0.25 mg ISL showed no significant differences versus controls in CD4+ cell count (MD = -6.35 cells/µL, p = 0.51) or total lymphocyte count changes (MD = -0.02 x 10 9 /L, p = 0.54). Statistically significant declines in CD4+ and lymphocyte counts were strictly restricted to the discontinued 0.75 mg dose. Overall adverse events and treatment discontinuations due to adverse events were comparable between groups. Conclusion: DOR/ISL provides non-inferior virologic efficacy compared with standard antiretroviral therapy with a favorable safety profile. The 0.25 mg Islatravir dose maintains antiviral efficacy while avoiding the immunologic declines observed with 0.75 mg dose, supporting its suitability as a simplified two-drug regimen. Registration: This review protocol was prospectively registered with PROSPERO ( CRD420261321479 ).

14 January 2026 in Aesthetic Surgery Journal Open Forum
Verified
Journal Article
Open access
MAMuhammad Tayyab Azam
Muhammad Tayyab Azam
MHMuhammad Hussain
Muhammad Hussain
MHMuhammad Hassan
Muhammad Hassan
SAShahzad Ashraf
Shahzad Ashraf
MKMuhammad Arif Khan
Muhammad Arif Khan
HAHasibullah Aminpoor
Hasibullah Aminpoor
Background: Upper facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment; yet, comprehensive synthesized evidence is limited. Objectives: To systematically evaluate the efficacy and safety of IncobotulinumtoxinA compared with placebo for the simultaneous treatment of UFLs in adults, following PRISMA 2020 guidelines. Methods: Comprehensive searches of PubMed, Embase, Cochrane CENTRAL, ICTRP, and ClinicalTrials.gov were performed to identify randomized controlled trials (RCTs) evaluating IncobotulinumtoxinA for combined UFLs treatment. The primary outcome was ≥1-grade improvement on Day 30. Secondary outcomes included ≥2-grade improvement and Global Aesthetic Improvement Scale (GAIS) scores. Safety outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs), and headaches. Results: Three RCTs (n = 704) were included. Pooled analysis using random-effects model demonstrated a significant ≥1-grade improvement at Day 30 in IncobotulinumtoxinA compared with placebo across all regions: GFLs (RR 21.49, 95% CI: 9.89-46.73), HFLs (RR 19.17, 95% CI: 9.23-39.80), and LCLs (RR 11.68, 95% CI: 7.49-18.20), all P < .00001. A ≥ 2-grade improvement similarly favored treatment across all areas (RRs 76.26-115.04; all P < .00001). Investigator-assessed GAIS scores also improved significantly (MD 2.29, 95% CI: 2.11-2.46, P < .00001). Serious AEs were lower with IncobotulinumtoxinA (RR 0.14, P = .03). There was no significant difference in TEAEs and headaches from placebo. Conclusions: IncobotulinumtoxinA demonstrates statistically significant efficacy and a comparable safety profile vs placebo for simultaneous UFLs treatment. These findings support its use in aesthetic practice, warranting further long-term investigation. Level of Evidence: 1 (Therapeutic): For image description, please refer to the figure legend and surrounding text.